US 12,144,843 B2
Methods and compositions for modulating myofibroblast activities
B. Chia Soo, Los Angeles, CA (US); Kang Ting, Los Angeles, CA (US); and Zhong Zheng, Van Nuys, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Jul. 14, 2020, as Appl. No. 16/928,724.
Application 15/673,880 is a division of application No. 14/106,617, filed on Dec. 13, 2013, granted, now 9,744,214, issued on Aug. 29, 2017.
Application 16/928,724 is a continuation in part of application No. 16/405,782, filed on May 7, 2019, granted, now 10,729,747.
Application 16/405,782 is a continuation of application No. 15/673,880, filed on Aug. 10, 2017, granted, now 10,279,010, issued on May 7, 2019.
Application 14/106,617 is a continuation of application No. PCT/US2012/042517, filed on Jun. 14, 2012.
Claims priority of provisional application 61/497,397, filed on Jun. 15, 2011.
Prior Publication US 2020/0345811 A1, Nov. 5, 2020
Int. Cl. A61K 38/18 (2006.01); A61K 38/17 (2006.01)
CPC A61K 38/1841 (2013.01) [A61K 38/17 (2013.01); A61K 38/1709 (2013.01)] 14 Claims
 
1. A composition without water, comprising an effective amount of fibromodulin peptide for promoting myofibroblast differentiation and apoptosis in a subject having a disorder associated with myofibroblast activity,
wherein the composition is in a controlled release formulation that provides controlled release of fibromodulin peptide, and
wherein the controlled release formulation comprises microparticles, thereby providing the effective amount of fibromodulin peptide for promoting myofibroblast differentiation and apoptosis, the effective amount of fibromodulin peptide being in a concentration of 0.01 mg/mL or from 0.4 mg/mL to 2.0 mg/mL.